FOURKITES
23.9.2022 09:01:38 CEST | Business Wire | Press release
Leading real-time supply chain visibility provider FourKites today published its global Premier Carrier List (PCL), which recognises the rapidly growing community of brokers, carriers and 3PLs who are achieving the highest standards of visibility-related operational excellence across all modes of transport.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220923005062/en/
FourKites’ Latest European Premier Carrier List Reflects ROI of High-quality Real-Time Supply Chain Visibility Data (Graphic: Business Wire)
To qualify for the PCL, carriers must demonstrate an ability to provide high-quality, consistent and accurate data on the vast majority of their shipments, thereby enabling their shipper customers and other ecosystem partners to streamline operations, increase the speed of shipping dock turn times, reduce inventory levels and optimise labour costs.
In the first half of 2022, 685 carriers were named to the PCL, which included an 8% increase for carriers based in Europe. These Premier Carriers demonstrated a significantly higher tracking percentage, on average, versus non-PCL carriers. Over the last six months, carriers who qualified for the Premier Carrier List tracked an average of 92.6% of their over-the-road shipments with real-time visibility, while non-PCL carriers tracked only 74.3% of their shipments.
“We partnered with FourKites because we wanted to grow our business,” says Vladas Stončius, CCO, Vlantana. “Increasingly, suppliers expect carriers to provide real-time data on all shipments. Thanks to FourKites, we’re able to do that efficiently and consistently, which has enabled us to win bigger customers and boost our margins.”
Notably, Premier Carriers witnessed higher growth rates than their non-PCL counterparts. In Europe, from H2 2021 to H1 2022, Premier Carriers experienced shipment volume growth of 9%, compared to non-PCL carriers in the region, who saw shipment volume contract 2%.
“Qualifying for FourKites’ Premier Carrier List is an increasingly important distinction for carriers, brokers and 3PLs who need to stand out in an increasingly competitive and volatile market,” said Jason Eversole, Vice President, Carrier Operations & Strategy, FourKites. “We’re pleased to see continued growth in the total number of Premier Carriers, and equally pleased to see the clear business benefits they are experiencing as a result of their visibility-related excellence.”
The Premier Carrier List is available here, where users can access and search the list according to carrier capabilities, transportation modes, geographies serviced and other relevant criteria.
Premier Carriers speak to program benefits:
"Transervice is honored to be recognised as a FourKites Premier Carrier. FourKites has enabled Transervice, and our clients, with unparalleled visibility into our logistics operations. This capability ensures complete transparency throughout the supply chain and promotes efficient resource utilisation. We are proud to partner with FourKites, and we look forward to their continued growth and innovation."
- Tom Poduch, Senior Director, Solutions, at Transervice
“Van den Bosch is always on the lookout for new opportunities to make its supply chain more efficient and sustainable. Fueled by data, insights and knowledge, innovation and digitalisation are key drivers. The qualification for Premier Carrier is a nice recognition and confirmation of our position as the supply changer in bulk.”
- Marrit Hopmans, Data & Applications Manager, Van den Bosch
“As a former employee of FourKites, I’ve experienced firsthand how imperative their technology is to the entire industry. TransLoop is extremely proud to be recognised as a FourKites Premier Carrier. We will continue to do whatever our shipper and carrier partners need us to do for TransLoop to be the most transparent and reliable broker partner in the industry.”
- Nick Reasoner, CEO, TransLoop
About FourKites
Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2.8 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching more than 200 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,100 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit www.fourkites.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220923005062/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom